Nouscom
  • Home
  • About
  • Technology
  • Pipeline
  • Investors
  • News
    • Grants
    • External presentations
    • Press Releases
    • Scientific publications
    • Conferences
  • Contact
Next-generation treatment for cancer Next-generation treatment for cancer Next-generation treatment for cancer Next-generation treatment for cancer
  • Home
  • About
  • Technology
  • Pipeline
  • Investors
  • News
    • Grants
    • External presentations
    • Press Releases
    • Scientific publications
    • Conferences
  • Contact

Archives

Monthly Archive for: "Marzo, 2023"
Home » Archivi per Marzo 2023
0

Nouscom Announces AACR 2023 Late-Breaking Presentation of Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy

BASEL, Switzerland – 15th March 2023 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector immunotherapies, today announced that new [...]

READ MORE
0

NOUSCOM ANNOUNCES THE PROMOTIONS OF LOREDANA SIANI TO VICE PRESIDENT OF TECHNICAL AND CMC DEVELOPMENT, TIFFANY BROOKE MULLER TO SENIOR VICE PRESIDENT OF FINANCE AND MORENA D’ALISE TO VICE PRESIDENT OF IMMUNOLOGY  

We are glad to announce the following promotions of our team members: Loredana Siani to Vice President of Technical and CMC Development, Tiffany Brooke Muller to Senior Vice President of Finance [...]

READ MORE
0

Nouscom announces appointment of Sarah Runswick as Senior Director of Clinical Science

We are thrilled to welcome Sarah Runswick as Senior Director of Clinical Science at Nouscom. Sarah is an experienced global clinical scientist with over 20 years expertise in early and late stage [...]

READ MORE
Contact
  • NOUSCOM
  • info@nouscom.com
  • nouscom.com
Our Privacy

Privacy Policy & Cookie Low

Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.

© Copyright 2018 | Made with by
error: Content is protected !!!